BioNTech Cuts 22% of Staff and Loses Its Founders — But a €16.8B Cash Hoard Gives the Turnaround Room to Breathe

BioNTech undergoes major restructuring: 22% job cuts, founder departure, and €16.8B cash reserves fund an oncology pivot with 15 late-stage trials.

BioNTech is embarking on the most dramatic transformation in its history, simultaneously shedding nearly a quarter of its workforce and parting ways with its founding scientists, while banking on an oncology pipeline that has yet to convince a sceptical market. The stock, trading at €78.10, sits roughly 26% below its 52-week peak and has fallen through all key moving averages — yet the company’s balance sheet tells a radically different story from its share price.

The shake-up is stark. By the end of 2027, BioNTech will close its production sites in Marburg, Idar-Oberstein and Tübingen, and its Singapore facility faces an uncertain future. Up to 1,860 roles — around 22% of the global workforce — are being eliminated. From 2029, management expects annual cost savings of roughly €500 million. The restructuring follows the expensive acquisition of CureVac’s manufacturing assets and marks a decisive shift away from the pandemic-era scale to a leaner, oncology-focused operation.

At the same time, the company is losing its founders. Professors Ugur Sahin and Özlem Türeci will leave by the end of 2026 to build an independent mRNA startup focused on early-stage innovations such as CAR-T cell therapies. Around 300 specialist researchers will transfer to the new entity. BioNTech retains a minority stake and rights to future milestone payments, but the leadership vacuum is real. The board has engaged executive search firm Egon Zehnder to find a new chief executive who can steer the late-stage oncology pipeline toward commercial reality by 2030.

That pipeline is already generating buzz among analysts. UBS upgraded the stock to Buy on May 26, setting a price target of $135, directly after BioNTech’s data presentations at the ASCO conference. At that meeting, Pumitamig combined with chemotherapy showed encouraging anti-tumour activity in first-line non-small cell lung cancer, while Gotistobart delivered durable responses in heavily pre-treated patients with platinum-resistant ovarian cancer — a potential chemo-free option. Earlier, at the European Lung Cancer Congress in March, Gotistobart had already demonstrated clinically meaningful survival improvements against the current standard in second-line squamous non-small cell lung cancer. The six additional Phase 3 starts planned for this year bring the total number of late-stage oncology studies to 15, with seven data readouts scheduled for 2026 alone.

Yet the market remains fixated on the near-term revenue slide. First-quarter 2026 revenue tumbled 35% year-on-year to just €118.1 million, producing a net loss of roughly €532 million. For the full year, BioNTech guides for total revenue of €2.0–€2.3 billion, with R&D spending of €2.2–€2.5 billion — implying continued operating losses as the company invests aggressively in its pipeline. That strategy is fully funded, however, by a cash and securities pile of €16.8 billion as of March 31. With a market capitalisation of around €18.8 billion, nearly 90% of the company’s equity value is backed by liquid assets. No capital raise is needed.

The bear case has clear ammunition: falling COVID vaccine sales, execution risk on the oncology pivot, and a leadership transition that creates genuine uncertainty. The stock’s 52-week low of €68.35 offers only about 14% downside from current levels, but the technical picture remains challenged — the relative strength index sits just below 50 and the share price is well beneath the 200-day moving average. Several analysts have trimmed their price targets, citing the leadership question.

Still, the consensus target stands at €106.24, implying 36% upside from today’s €78.10. For investors willing to look past the near-term earnings dip, the calculus is simple: the pipeline optionality is being discounted heavily, the balance sheet provides a multi-year runway, and the restructuring — brutal as it is — strips away legacy costs to make way for an oncology-focused future. The market is still pricing BioNTech as a post-COVID casualty. The data accumulating across its 15 Phase 3 trials suggests otherwise.